Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.56 |
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | CALML3 | P27482 | 1/20 | 0.56 |
| ▸ | SDHA | P31040 | 1/20 | 0.56 |
| ▸ | F10 | P00742 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18402655 | 0.90 | MAOA (0.55) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL1033023 | 0.89 | MAOA (0.70) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL1033024 | 0.89 | MAOA (0.70) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL13054893 | 0.88 | F10 (0.66) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL12964559 | 0.87 | MAOA (0.56) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL16746663 | 0.87 | MAOA (0.49) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL1034798 | 0.85 | MAOA (0.54) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL1034799 | 0.85 | MAOA (0.54) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5917566 | 0.85 | MAOB (0.71) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL21999384 | 0.84 | MAOA (0.53) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052399-A1 | Oxazolidinone derivatives as antibacterial agents | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1575944-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIBACTERIAL AGENTS | Astrazeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004056819-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052399-A1 | Oxazolidinone derivatives as antibacterial agents | H1-3, MRPL21, ATAD3B | MAOA 253/4885MAOB 80/4885LMNA 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.